MIRA Pharmaceuticals Reports MIRA-55 Pain Relief Comparable to Celebrex in Preclinical Study

MIRA PHARMACEUTICALS, INC. (MIRA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide SKNY-1’s Weight Reduction Without Significant Changes in Food Consumption Suggests a Pot

MIRA Pharmaceuticals reported that its drug MIRA-55 showed pain relief comparable to celecoxib in a 21-day preclinical study. The company plans to submit an IND application in Q1 2027, pending completion of required activities. The study demonstrated sustained effects without observed tolerance and reduced swelling.

MIRA PHARMACEUTICALS, INC. (MIRA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site Initiation MIAMI, Sept. 17, 2026

MIRA Pharmaceuticals (NASDAQ:MIRA) shares were flat at the open. The company said new preclinical pharmacology data for its cannabinoid analog Mira-55 in chronic inflammatory pain showed a THC-like receptor profile but different effects, including an anxiolytic effect not seen with THC. MIRA also referenced March 2026 animal data versus rimonabant.

Coherus Oncology reported interim phase 1b trial results showing tagmokitug, combined with Loqtorzi and chemotherapy, achieved a 75% overall response rate in esophageal cancer patients as a first-line therapy, regardless of PD-L1 status, according to the company.

Rio Tinto opened two lithium plants in Argentina, investing $1.4B to add 25,000 metric tons of lithium carbonate annually. The company aims to reach 200,000 tons by 2028, using DLE technology. Argentina's reforms and lithium reserves position it as a key player in the global market.